LEXINGTON, Mass., March 1, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology companydevoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Friday, March 8, 2019, at 8:00 a.m.
After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.
About Aldeyra TherapeuticsAldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Corporate Contact:David McMullinAldeyra Therapeutics, Inc.Tel: 781-761-4904 ext. 218 firstname.lastname@example.org
Investor Contact:Chris BrinzeyWestwicke, an ICR Company Tel: 339-970-2843Chris.email@example.com
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-report-fourth-quarter-and-full-year-2018-financial-results-and-host-conference-call-on-friday-march-8-2019-300804722.html
SOURCE Aldeyra Therapeutics, Inc.
Subscribe to our Free Newsletters!